Otsuka Holdings (4578) · InitiativeAchieved
Acquisition of an ADC drug discovery platform through the acquisition of Araris Biotech
First written in FY2024. 1 of 2 entries say "Achieved", first in FY2025-H1. Latest entry: FY2025-H1.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Acquisition of an ADC drug discovery platform through the acquisition of Araris BiotechA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2025-H1AchievedAnnual report
「Otsuka Pharmaceutical acquired 100% of the voting shares of Araris in exchange for cash and future milestone payments. The acquisition date was 31 March 2025.」
The acquisition of Araris Biotech AG as a wholly owned subsidiary was completed on 31 March 2025, bringing the AraLinQ™ ADC linker platform and 3 preclinical products into the Group. - FY2024First statedAnnual report
「Taiho Pharmaceutical agreed on 17 March 2025 to acquire Araris Biotech AG, a Switzerland-based biotechnology company developing next-generation antibody-drug conjugates (ADCs), as a wholly owned subsidiary through an acquisition of shares in exchange for cash and future milestone payments, and entered into an agreement to that effect.」
The Group entered into an agreement to acquire Araris, which has the AraLinQ™ ADC linker platform and 3 preclinical products. The consideration is expected to be US$400 million upon completion, with additional milestone payments of up to US$740 million, and completion is scheduled for the first half of fiscal 2025.